- Home
- TLS vs CRVS Comparison
TLS vs CRVS Comparison
Compare TLS & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLS
- CRVS
- Stock Information
- Founded
- TLS 1969
- CRVS 2014
- Country
- TLS United States
- CRVS United States
- Employees
- TLS N/A
- CRVS N/A
- Industry
- TLS EDP Services
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- TLS Technology
- CRVS Health Care
- Exchange
- TLS Nasdaq
- CRVS Nasdaq
- Market Cap
- TLS 508.2M
- CRVS 459.0M
- IPO Year
- TLS 2020
- CRVS 2016
- Fundamental
- Price
- TLS $6.79
- CRVS $7.19
- Analyst Decision
- TLS Hold
- CRVS Strong Buy
- Analyst Count
- TLS 4
- CRVS 3
- Target Price
- TLS $4.83
- CRVS $13.00
- AVG Volume (30 Days)
- TLS 968.3K
- CRVS 772.5K
- Earning Date
- TLS 11-11-2025
- CRVS 11-11-2025
- Dividend Yield
- TLS N/A
- CRVS N/A
- EPS Growth
- TLS N/A
- CRVS N/A
- EPS
- TLS N/A
- CRVS N/A
- Revenue
- TLS $116,739,000.00
- CRVS N/A
- Revenue This Year
- TLS $47.80
- CRVS N/A
- Revenue Next Year
- TLS $26.19
- CRVS N/A
- P/E Ratio
- TLS N/A
- CRVS N/A
- Revenue Growth
- TLS N/A
- CRVS N/A
- 52 Week Low
- TLS $1.83
- CRVS $2.54
- 52 Week High
- TLS $7.33
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- TLS 56.34
- CRVS 67.47
- Support Level
- TLS $6.58
- CRVS $7.03
- Resistance Level
- TLS $7.33
- CRVS $7.59
- Average True Range (ATR)
- TLS 0.38
- CRVS 0.41
- MACD
- TLS -0.10
- CRVS 0.06
- Stochastic Oscillator
- TLS 32.92
- CRVS 78.89
About TLS Telos Corporation
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).